Aurobindo's CuraTeQ Wins Canada Nod for Cancer Biosimilar

Aurobindo Pharma’s biosimilars arm CuraTeQ Biologics has secured a major regulatory milestone, as it wins Canada nod for its cancer biosimilar, marking a significant step in the company’s global expansion in oncology treatments.

In a regulatory filing, the company said that CuraTeQ Biologics has received a Notice of Compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate. The approval is for Bevqolva, a bevacizumab biosimilar used in the treatment of multiple types of cancer.

The NOC indicates that the drug has met Canada’s strict standards for safety, quality, and efficacy. It also confirms that the biosimilar is comparable to the reference biologic medicine under regulatory guidelines, allowing it to be marketed in the country.

Bevqolva is a monoclonal antibody that works by targeting vascular endothelial growth factor (VEGF), a protein that helps tumors form new blood vessels. By blocking this process, the drug helps slow down the growth and spread of cancer, particularly in conditions such as colorectal and lung cancers.

Also Read: Bristol Myers Beats Estimates on Drug Sales Surge

The biosimilar will be available in both 100 mg and 400 mg doses. Its reference product, Avastin, is globally marketed by Roche and its US-based partner Genentech.

This approval adds to CuraTeQ’s growing global footprint. The product has already been cleared in the UK and is currently under review by the European Medicines Agency, reflecting the company’s strategy to expand across multiple international markets.

CuraTeQ continues to strengthen its biosimilars pipeline, with several products under development and review in key regions. It also has additional applications being evaluated by Health Canada, suggesting more approvals could follow.

The latest development highlights Aurobindo Pharma’s increasing focus on complex biologics and its ambition to build a strong position in the global biosimilars space. As demand rises for affordable cancer treatments, such approvals are expected to improve patient access while increasing market competition in the oncology segment.